INVITES BIOCORE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8,800 KRW | -3.30% |
|
-2.87% | -5.38% |
More news
| 1 day | -3.30% | ||
| 1 week | -2.87% | ||
| Current month | -2.98% | ||
| 1 month | -2.98% | ||
| 3 months | -6.38% | ||
| 6 months | -11.02% | ||
| Current year | -5.38% |
1 week
8 610.00
9 380.00
1 month
7 810.009 810.00
Current year
7 810.0010 000.00
1 year
7 800.0011 990.00
3 years
6 100.0014 200.00
5 years
2 765.0017 450.00
10 years
2 765.0017 450.00
| Managers | Title | Age | Since |
|---|---|---|---|
Moon-Ki Hong
DFI | Director of Finance/CFO | 50 | - |
Seung-Yong Hwang
CTO | Chief Tech/Sci/R&D Officer | 58 | 14-11-30 |
Ho-Young Lee
HRO | Human Resources Officer | 60 | 13-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Seung-Yong Hwang
CTO | Chief Tech/Sci/R&D Officer | 58 | 14-11-30 |
Dong-Gyu Ahn
BRD | Director/Board Member | 63 | - |
Yong-Gyu Shin
CHM | Chairman | 56 | - |
Invites Biocore Co Ltd, formerly BioCore Co Ltd, is a Korea-based company mainly engaged in the provision of medical examination services. The Company operates its business through two segments. The New Drug Development Business segment is involved in the provision of bioequivalence testing, drug in vivo kinetics research, drug analysis in biological samples, toxicity kinetics testing, microanalysis in pharmaceuticals, comparative dissolution testing, and clinical trial consulting. The Biotechnology Business segment is engaged in the provision of customized genome analysis services and the manufacture and sale of diagnostic kits. The Companyâs products are sold under the brand of Bio-Core.
| 1st Jan change | Capi. | |
|---|---|---|
| -5.38% | 51.01M | |
| -19.78% | 10.81B | |
| +44.90% | 3.36B | |
| -33.46% | 2.22B | |
| -14.31% | 2.16B | |
| -28.86% | 1.55B | |
| +25.34% | 1.04B | |
| -3.28% | 746M | |
| -35.33% | 425M | |
| -46.53% | 405M |
- Stock Market
- Equities
- A216400 Stock
